Anika Therapeutics (ANIK) Amortization of Goodwill (2020)

Anika Therapeutics' (ANIK) quarterly Amortization of Goodwill came in at $24.4 million in Q4 2020.

Anika Therapeutics (ANIK) Amortization of Goodwill (2020) Analysis & Trends

Anika Therapeutics (ANIK) has 1 years of Amortization of Goodwill data on file, last reported at $24.4 million in Q4 2020.

  • On a quarterly basis, Amortization of Goodwill changed N/A year-over-year to $24.4 million in Q4 2020; TTM through Sep 2021 was $24.4 million, a N/A change from a year earlier, with the FY2020 full-year figure at $42.5 million, changed N/A from the prior year.
  • Amortization of Goodwill for Q4 2020 stood at $24.4 million.
  • Over the last five years, Amortization of Goodwill for ANIK reached as high as $24.4 million in Q4 2020 and fell as low as $24.4 million in Q4 2020.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Haleon 87.22 Bn 85.35 Bn -
2 Teva Pharmaceutical Industries 39.60 Bn 35.87 Bn 1.97 Bn
3 Zoetis 31.46 Bn 29.52 Bn 1.62 Bn
4 Takeda Pharmaceutical 26.49 Bn 22.44 Bn 4.39 Bn
5 United Therapeutics 23.03 Bn 20.88 Bn 648.10 Mn
6 Universe Pharmaceuticals 23.03 Bn -10.56 Bn -
7 Viatris 20.90 Bn 19.09 Bn 1.16 Bn
8 Neurocrine Biosciences 17.50 Bn 16.19 Bn 800.70 Mn
9 Elanco Animal Health 12.33 Bn 11.91 Bn 785.00 Mn
10 Anika Therapeutics 198.50 Mn 131.71 Mn 19.00 Mn

Historic Data

Download Data
DateValue
Dec 31, 2020 24.40 Mn
Dec 31, 2020 24.40 Mn